TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06003244

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 6-minute walk distance (6MWD) test
Description: 6-minute walk distance (6MWD) test will be performed according to clinical standards

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6-minute walk distance (6MWD) test with supplemental oxygen (3 l/min, nasal)
Description: 6-minute walk distance (6MWD) test will be performed according to clinical standards additionally with supplemental oxygen therapy (3l/min, nasal)
Study: NCT05702788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib hydrochloride tablets
Description: 75mg of Jaktinib administered orally Twice daily(BID) with best available treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib hydrochloride tablets
Description: 100mg of Jaktinib administered orally Twice daily(BID) with best available treatment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (given as two placebo tablets) administered orally BID with best available treatment.
Study: NCT04759872

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic-euglycemic Clamp
Description: Participants will be administered a constant-rate insulin infusion (to induce mild hyperinsulinemia), with an infusion of dextrose to maintain blood glucose concentration (to maintain euglycemia).
Study: NCT05885074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin Arm
Description: The subject will be randomized, in a double-blind manner to Empagliflozin 25mg once daily for a period of 12 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Arm
Description: The subject will be randomized, in a double-blind manner to receive placebo once daily for a period of 12 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise capacity VO2 maximum determination
Description: Each participant's maximal oxygen capacity will be determined using a modified Bruce treadmill protocol and will also undergo a DEXA scan to determine the body mass.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise capacity VO2 maximum determination
Description: Each participant's maximal oxygen capacity will be determined using a modified Bruce treadmill protocol and will also undergo a DEXA scan to determine the body mass.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Challenge
Description: Each participant will walk at 70 % of his/her VO2max for 20 minutes on treadmill and will also undergo a resting energy expenditure test.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise Challenge
Description: Each participant will walk at 70 % of his/her VO2max for 20 minutes on treadmill and will also undergo a resting energy expenditure test.
Study: NCT04693507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teverelix TFA 120 mg
Description: Teverelix TFA 240 mg Day 0 and 120 mg every 6 weeks from week 6 to week 24

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teverelix TFA 180 mg
Description: Teverelix TFA 360 mg Day 0 and 180 mg every 6 weeks from week 6 to week 24
Study: NCT04901494

Intervention type: DRUG
Intervention: SSRI
Description: Selective serotonin reuptake inhibitor

Intervention type: DRUG
Intervention: SSRI
Description: Selective serotonin reuptake inhibitor
Study: NCT04976946

Intervention type: OTHER
Intervention: Comprehensive questionnaire
Description: Multi-staged, international Delphi study that aims to establish criteria for standardised complication reporting in Urology.

Intervention type: OTHER
Intervention: Comprehensive questionnaire
Description: Multi-staged, international Delphi study that aims to establish criteria for standardised complication reporting in Urology.

Intervention type: OTHER
Intervention: Comprehensive questionnaire
Description: Multi-staged, international Delphi study that aims to establish criteria for standardised complication reporting in Urology.
Study: NCT05298540

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based computerised cognitive training with BrainHQ
Description: Participants will be registered for individual accounts to an online CCT program created by BrainHQ (Posit Science, San Francisco), that can be administered using their own computer or tablet. BrainHQ has been associated with improvements in memory, attention, and processing speed. The program will be customised to target domains thought to be deficient in the postoperative period and will include training in memory, attention, and processing speed. Specifically, the following six games have been selected: hear, hear (auditory memory and attention), to-do list training (working memory), divided attention (attention), target tracker (attention), double decision (useful field of view and visual processing speed), and eye for detail (visual processing speed and visual working memory). The exercises are adaptive, adjusting the application difficulty to the participants performance.
Study: NCT01564472

Intervention type: OTHER
Intervention: PSG Scoring
Description: No participants will be enrolled and no interventions, besides PSG scoring will be utilized.
Study: NCT05036291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NB004 tablets
Description: Part1: Dose escalation phase of study drug NB004 monotherapy:~Drug: NB004 tablets~NB004 tablets will be administered orally once daily for repeated 28-day cycles until discontinuation criteria are met.~Part 2: Dose Escalation Phase/ COMBO Dose Expansion Phase for the NB004 in combination with Sotorasib:~Drug: NB004 tablets \& Sotorasib~NB004 tablets will be administered orally once a daily for repeated 21-day cycles until discontinuation criteria are met.~Sotorasib will be administered with the recommended dosage per prescribing information approved by the FDA~Part 3: Dose Escalation Phase/ COMBO Dose Expansion Phase for the NB004 in combination with Sotorasib:~Drug: NB004 tablets \& Sotorasib~NB004 tablets will be administered orally once daily for repeated 21-day cycles until discontinuation criteria are met.~Sotorasib will be administered with the recommended dosage per prescribing information approved by the FDA .
Study: NCT04708002

Intervention type: OTHER
Group type: OTHER
Intervention: early integrated palliative approach model
Description: From the construction of a common vision of palliative care between actors inside and outside the nursing home to the sustainability of palliative care in nursing home.

Intervention type: OTHER
Group type: OTHER
Intervention: early integrated palliative approach model
Description: From the construction of a common vision of palliative care between actors inside and outside the nursing home to the sustainability of palliative care in nursing home.

Intervention type: OTHER
Group type: OTHER
Intervention: early integrated palliative approach model
Description: From the construction of a common vision of palliative care between actors inside and outside the nursing home to the sustainability of palliative care in nursing home.

Intervention type: OTHER
Group type: OTHER
Intervention: early integrated palliative approach model
Description: From the construction of a common vision of palliative care between actors inside and outside the nursing home to the sustainability of palliative care in nursing home.
Study: NCT06342596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-LY3473329
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-LY3473329
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3473329
Description: Administered orally
Study: NCT06297473

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-/video follow-up
Description: The yearly routine review of patients takes place by using a telephone or video interview rather than in-person interview in the endocrine outpatient department.~All other assessments, e.g. biochemical, MRI, is conducted as usual.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-person follow-up
Description: The yearly routine review on patients takes place at the endocrine outpatient department
Study: NCT06212830

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Gabapentin 200 mg twice a day, starting from the night prior to the procedure and continue 48 hours after

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Targin
Description: Targin 5 mg twice a day after the procedure for 48 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID
Description: Nurofen (NSAID) 200 mg twice a day after the procedure for 48 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID
Description: Nurofen (NSAID) 200 mg twice a day after the procedure for 48 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID
Description: Nurofen (NSAID) 200 mg twice a day after the procedure for 48 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Paracetamol 500 mg every 4 hours during waking hours after the procedure for 48 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Paracetamol 500 mg every 4 hours during waking hours after the procedure for 48 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Paracetamol 500 mg every 4 hours during waking hours after the procedure for 48 hours
Study: NCT06147583

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation of an insulin pump failure
Description: The intervention will consist in simulating an insulin pump failure by suspending insulin infusion and monitoring the consequent hyperglycemia.
Study: NCT04457492

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of FES to the Face
Description: Functional electrical stimulation (FES) for facial paralysis is a technique in which muscles are electrically stimulated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of FES to the Face
Description: Functional electrical stimulation (FES) for facial paralysis is a technique in which muscles are electrically stimulated.
Study: NCT05412953

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaire

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tonation Breathing Technique
Description: Participate in tonation breathing techniques
Study: NCT05253092

Intervention type: OTHER
Group type: OTHER
Intervention: Virtual mindfulness meditation
Description: Subjects will participate in 30 minutes of a virtual mindfulness meditation session, totaling eight sessions.
Study: NCT06757894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zuberitamab
Description: 375 mg/m², administered on Day 1 (D1) of Cycles 1-6 (C1-C6)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: 90 mg/m², administered on D1-2 of C1-C6
Study: NCT06756594

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine-Propofol
Description: efficacy of sedation with Dexmedetomidine-Propofol combination in the upper or lower gastrointestinal system endoscopy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine-Propofol
Description: efficacy of sedation with Ketamine-Propofol combination in the upper or lower gastrointestinal system endoscopy.
Study: NCT06524817

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: Neuronavigated Theta-Burst Transcranial Magnetic Stimulation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: Neuronavigated Theta-Burst Transcranial Magnetic Stimulation
Study: NCT06194227

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-speed, Cognitive Challenge Yoga
Description: Participants in this group will receive in-person high-speed yoga with cuing 3 times per week for 24 consecutive weeks for a total of 72 training sessions of 1 hour duration. Subjects will move as quickly as possible from one pose to another.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Yoga
Description: Participants will perform in-person controlled speed Hatha yoga 3 times per week for 24 weeks for a total of 72 sessions of 1 hour duration.
Study: NCT05677906

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking only (Step It Up!)
Description: Participants will meet weekly for 60 minutes and walk together as a group. Participants will progressively build up to walking for 45 minutes at a brisk pace. Walks will start with a check-in and end with stretching as a group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking only (Step It Up!)
Description: Participants will meet weekly for 60 minutes and walk together as a group. Participants will progressively build up to walking for 45 minutes at a brisk pace. Walks will start with a check-in and end with stretching as a group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined (Step It Up! plus Civic Engagement)
Description: Participants in the combined groups will meet weekly for 90 minutes with group members. They will participate in a group walk for 60 minutes followed by 30 minutes of civic engagement aimed at improving walkability in the community
Study: NCT04884139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir/Lamivudine as a single pill
Description: - Dose: Dolutegravir 50mg/ Lamivudine 300 mg -Route of adminstration: oral -Schedule of administration: once a day for 96 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bictegravir/Emtricitabine/Tenofovir alfenamide as a single pill.
Description: * Dose: Bictegravir 50 mg/Emtricitabine 200 mg /Tenofovir alafenamide 25 mg~* Route of adminstration: oral~* Schedule of administration: once a day for 96 weeks.
Study: NCT05581381

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: empathy training program
Description: Empathy training, a total of 8 weeks of training (1 time a week, 1 hour each time)
Study: NCT04927949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cangrelor perfusion during PCI
Description: Cangrelor perfusion (started before PCI) with intravenous bolus of 30 microgram/kg, followed by a perfusion of 4 microgram/kg/min during 2 hours or until the end of the PCI if longer
Study: NCT05232903

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SVF therapy group
Description: The active treatment is an intravenous injection with the stromal vascular fraction (SVF) harvested from the patient's own fatty tissue.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SVF therapy group
Description: The active treatment is an intravenous injection with the stromal vascular fraction (SVF) harvested from the patient's own fatty tissue.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SVF therapy group
Description: The active treatment is an intravenous injection with the stromal vascular fraction (SVF) harvested from the patient's own fatty tissue.
Study: NCT04810806

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate coronary angiography within 2 hours after randomization
Description: After achievement of informed consent in patients with NSTE-ACS complicated by ADHF, patients will be screened and randomized. Patients will be randomized to immediate CAG group or delayed CAG group. Immediate CAG group will receive CAG within 2 hours after randomization. Patients will receive treatment methods according to CAG results: percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or medical therapy only by operators' discretion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed coronary angiography after stabilization of heart failure
Description: After achievement of informed consent in patients with NSTE-ACS complicated by ADHF, patients will be screened and randomized. Patients will be randomized to immediate CAG group or delayed CAG group. Delayed CAG group will receive CAG after stabilization of ADHF; improvement of symptoms and signs of heart failure. Patients will receive treatment methods according to CAG results: percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or medical therapy only by operators' discretion.
Study: NCT04927949

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: standard PCI
Description: primary PCI without cangrelor

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: standard PCI
Description: primary PCI without cangrelor
Study: NCT05052151

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low dialysate temperature
Description: 35°C

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High dialysate temperature
Description: 37°C

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low dialysate bicarbonate concentration
Description: 30 mmol/L

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High dialysate bicarbonate concentration
Description: 38 mmol/L
Study: NCT04712279

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin 0.6mg/kg/day
Description: Use of ivermectin 0.6m/kg/day q.d.for 05 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin 1.0mg/kg/day
Description: Ivermectin 1.0mg/kg/day q.d. for 05 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo q.d.for 05 days
Study: NCT06341309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Liposome
Description: 70 mg/m\^2 , d1, 14 days per cycle. Until the disease progresses, intolerable toxicity occurs, and the patient withdraws informed consent (whichever comes first).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5mg/kg, d1, 14 days per cycle. Until the disease progresses, intolerable toxicity occurs, and the patient withdraws informed consent (whichever comes first).
Study: NCT04712279

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 200mg/day q.d. for 05 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 200mg/day q.d. for 05 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 200mg/day q.d. for 05 days
Study: NCT04735289

Intervention type: OTHER
Intervention: EPIC-COS Food Frequency Questionnaire diet Evaluation
Description: Anthropometric measurements (Body mass Index, Lean and fat body composition evaluation) and diet habits evaluation with EPIC-COS-FFQ

Intervention type: OTHER
Intervention: EPIC-COS Food Frequency Questionnaire diet Evaluation
Description: Anthropometric measurements (Body mass Index, Lean and fat body composition evaluation) and diet habits evaluation with EPIC-COS-FFQ
Study: NCT06503120

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean-diet intervention group
Description: Dietitian-guided Nutritionist Education Process
Study: NCT04735289

Intervention type: OTHER
Intervention: Metabolome, Microbiota, Lymphocytes subpopulations
Description: At diagnosis before any treatment for bone sarcoma will be obtained :~1. a blood sample for metabolomics analyses~2. a stool sample for microbiota analysis~3. Lymphocyte subpopulations (CD3, CD4, CD8, NK) will be analyzed in blood samples
Study: NCT04849429

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma (PRP) with exosomes
Description: Autologous Platelet rich plasma (PRP) with exosomes Following skin disinfection of the back 2 ml from the total PRPex procured will be injected as soon as possible by an fluoroscopy guided lateral approach.
Study: NCT06503120

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: A 10-minute talk on the epidemiology of MASLD and balanced diet, resembling routine clinical practice.
Study: NCT04672850

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: The participants will consume 2 capsules daily for three months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participants will consume 2 capsules daily for three months
Study: NCT04519853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Glycemic Load Diet
Description: Food delivery service will provide a low glycemic load diet for 8 weeks
Study: NCT04849429

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: placebo : 2 ml normal saline para discal administration
Study: NCT05365256

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard distraction during chemotherapy treatment period
Description: habitual distraction of patients during chemotherapy sessions authorized as part of routine care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual distraction during chemotherapy treatment period
Description: A virtual reality headset will be worn for 15 minutes per hour of treatment
Study: NCT05579717

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Equine Assisted Learning
Description: EAL is an intervention in which mental health clinicians and equine specialists work together with clients to address a learning goal via unmounted interaction with a horse. It is 16 sessions in length, at a rate of two sessions per week.
Study: NCT04899167

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI 1.5T and 3.0T
Description: Magnetic Resonance Imaging for Renal Fibrosis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI 1.5T and 3.0T
Description: Magnetic Resonance Imaging for Renal Fibrosis
Study: NCT04576897

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Velacur
Description: Ultrasound elasticity imaging
Study: NCT04708509

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extubation Advisor
Description: Participants undergoing a Spontaneous Breathing Trial (SBT) to assess readiness for extubation will be connected to a portable monitor displaying ECG, capnography, and other waveforms. This monitor will also be connected to a laptop containing the Extubation Advisor (EA) software. During the SBT, relevant patient information will be entered into the EA application and the EA application will record waveform data. When the SBT is complete, the EA application will analyze the waveform and patient data to generate a score summarizing the risk of extubation failure. A report will be generated and provided to the respiratory therapist and attending physician to help determine whether to proceed with extubation or not. Patients will be followed for 72 hours after extubation, when the clinical outcome case report form will be completed.